Back

Effects of SGLT2 inhibitors on hyperuricemia in patients with chronic heart failure with reduced ejection fraction.

30 August 2025 (14:15 - 15:00)
Organised by: Logo
Congress Presentation Part of: Heart failure with reduced ejection fraction (HFrEF) (2) Heart Failure with Reduced Ejection Fraction (HFrEF) ESC Professional Premium Access ESC Congress 2025 European Society of Cardiology

About the speaker

Photo
Professor Nabil Naser

Polyclinic Dr. Nabil - Faculty of Medicine University of Sarajevo, Sarajevo (Bosnia and Herzegovina)

2 More presentations in this session

Presentation thumbnail
Iron deficiency and anemia in heart failure with mildly reduced ejection fraction and their impact on prognosis and right ventricular-pulmonary artery coupling
Doctor Y. Fukunaga (Tokyo, JP)
Abstract Slides Video
Presentation thumbnail
Platelet counts and prognosis in heart failure with mildly reduced ejection fraction: results from a large-scale registry
Mr J. Dudda (Mannheim, DE)
Abstract Slides Video

Access the full session

Session thumbnail
Heart failure with reduced ejection fraction (HFrEF) (2)

The Event

Event poster

ESC Congress 2025

30 August 2025 14:15 CET
You may be interested in
thumbnail
Congress Presentation
Evaluation of the effects of the Sodium-glucose cotransporter 2 inhibitors and sacubitril/valsartan combined therapy in patients with HFrEF: echocardiographic study.
thumbnail
Congress Session
Further Insights into SGLT2i treatment for heart failure
thumbnail
Congress Presentation
Canagliflozin improves hemodynamic parameters by impedance cardiography and left ventricular diastolic function in patients with type 2 diabetes mellitus

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources